Manuscripts

Search by keyword, year, or author name.

Showing 1573 manuscripts.

Virologic and Immunologic Correlates with the Magnitude of Antibody Responses to the Hepatitis A Vaccine in HIV-Infected Children on HAART

Adriana Weinberg, Sharon Huang, Terence Fenton, Julie A. Patterson, Philimon Gona, Jennifer S. Read, Wayne M. Dankner, Sharon Appelbaum Nachman. Virologic and Immunologic Correlates with the Magnitude of Antibody Responses to the Hepatitis A Vaccine in HIV-Infected Children on HAART. Journal of Acquired Immune Deficiency Syndromes. 2009. 51: 54-9. PMID: 19617848

Year

2009

Journal

Journal of Acquired Immune Deficiency Syndromes

Study

P1008

Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy antiretroviral Therapy.

Allison Agwu, Jane C. Lindsey, Kimberly Ferguson, Hao Zhang, Stephen A. Spector, Bret J. Rudy, Stuart C. Ray, Steven D. Douglas, Patricia M. Flynn, Deborah Persaud. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy antiretroviral Therapy.. AIDS Patient Care and STDs. 2009. 22: 545-52.

Year

2009

Journal

AIDS Patient Care and STDs

Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.

Philip Keiser, David Alain Wohl, Michelle A. Kendall, Janet Andersen, Clyde S. Crumpacker, Stephen A. Spector, Judith Feinberg, Beverly L. Alston-Smith, Susan Owens, Suzette A. Chafey, Michael Marco, Sharon D. Maxwell-Henkel, Nell Lurain, Douglas Jabs, Constance A. Benson. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.. HIV Clinical Trials. 2009. 10: 143-52. PMID: 19632953

Year

2009

Journal

HIV Clinical Trials

Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)

David B. Clifford, Scott Evans, Yijun Yang, Edward P. Acosta, Heather Ribaudo, Roy (Trip) Gulick. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clinical Trials. 2009. 10: 343-55.

Year

2009

Journal

HIV Clinical Trials

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection

Susan Moir, Angelina Malaspina, Irini Sereti, Michel Morre, Richard Dunham, Renaud Buffet, John Spritzler, Guido Silvestri, Evgenia Aga, Michael M. Lederman, Michael Proschan, Kathleen A. Medvik, Cathy Battaglia, Alan Landay, Savita G. Pahwa, Margaret A. Fischl, David M. Asmuth, Allan R. Tenorio, John Altman, Lawrence Fox. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood. 2009. 113: 6304-14.

Year

2009

Journal

Blood

A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients

Lisa M. Demeter, Hongyu Jiang, Lisa Mukherjee, Gene D. Morse, Robin DiFrancesco, Robert DiCenzo, Carrie Dykes, Prakash Sista, Lee Bacheler, Karin L. Klingman, Alex R. Rinehart, Mary Albrecht. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. AIDS. 2009. 23: 357-68.

Year

2009

Journal

AIDS